Vai direttamente al contenuto

Oncologia

Chemioterapia personalizzata o modificata (variazione nel dosaggio o nei tempi di somministrazione)

Combined lenalidomide, low-dose dexamethasone, and rituximab achieves durable responses in rituximab-resistant indolent and mantle cell lymphomas. (apre una nuova finestra)

Ahmadi T, Chong EA, Gordon A, Aqui NA, Nasta SD, Svoboda J, Mato AR, Schuster SJ.

Fonte‎: Cancer 2014;120(2):222-8.

Indicizzato‎: PubMed 24122387

DOI‎: 10.1002/cncr.28405

https://www.ncbi.nlm.nih.gov/pubmed/24122387 (apre una nuova finestra)

Autologous stem-cell transplantation can be performed safely without the use of blood-product support. (apre una nuova finestra)

Ballen KK, Becker PS, Yeap BY, Matthews B, Henry DH, Ford PA.

Fonte‎: J Clin Oncol 2004;22(20):4087-94.

Indicizzato‎: PubMed 15353543

DOI‎: 10.1200/JCO.2004.01.144

https://www.ncbi.nlm.nih.gov/pubmed/15353543 (apre una nuova finestra)

The use of blood conservation methods in addition to erythropoietin allows myeloablative allogeneic stem cell transplantation without the use of blood products. (apre una nuova finestra)

Ciurea S, Beri R, Dobogai L, Chunduri S, Mahmud N, Rondelli D, Peace D.

Fonte‎: Bone Marrow Transplant 2006;37(3):325-7.

Indicizzato‎: PubMed 16314850

DOI‎: 10.1038/sj.bmt.1705223

https://www.ncbi.nlm.nih.gov/pubmed/16314850 (apre una nuova finestra)

Oral azacitidine (CC-486) for the treatment of myelodysplastic syndromes and acute myeloid leukemia. (apre una nuova finestra)

Cogle CR, Scott BL, Boyd T, Garcia-Manero G.

Fonte‎: Oncologist 2015;20(12):1404-12.

Indicizzato‎: PubMed 26463870

DOI‎: 10.1634/theoncologist.2015-0165

https://www.ncbi.nlm.nih.gov/pubmed/26463870 (apre una nuova finestra)

Hematologic improvement and response in elderly AML/RAEB patients treated with valproic acid and low-dose Ara-C. (apre una nuova finestra)

Corsetti MT, Salvi F, Perticone S, Baraldi A, De Paoli L, Gatto S, Pietrasanta D, Pini M, Primon V, Zallio F, Tonso A, Alvaro MG, Ciravegna G, Levis A.

Fonte‎: Leuk Res 2011;35(8):991-7.

Indicizzato‎: PubMed 21474179

DOI‎: 10.1016/j.leukres.2011.02.021

https://www.ncbi.nlm.nih.gov/pubmed/21474179 (apre una nuova finestra)

Arsenic trioxide during consolidation for patients with previously untreated low/intermediate risk acute promyelocytic leukaemia may eliminate the need for maintenance therapy. (apre una nuova finestra)

Coutre SE, Othus M, Powell B, Willman CL, Stock W, Paietta E, Levitan D, Wetzler M, Attar EC, Altman JK, Gore SD, Maher T, Kopecky KJ, Tallman MS, Larson RA, Appelbaum FR.

Fonte‎: Br J Haematol 2014;165(4):497-503.

Indicizzato‎: PubMed 24528179

DOI‎: 10.1111/bjh.12775

https://www.ncbi.nlm.nih.gov/pubmed/24528179 (apre una nuova finestra)

Dose-dense rituximab-CHOP compared with standard rituximab-CHOP in elderly patients with diffuse large B-cell lymphoma (the LNH03-6B study): a randomised phase 3 trial. (apre una nuova finestra)

Delarue R, Tilly H, Mounier N, Petrella T, Salles G, Thieblemont C, Bologna S, Ghesquières H, Hacini M, Fruchart C, Ysebaert L, Fermé C, Casasnovas O, Van Hoof A, Thyss A, Delmer A, Fitoussi O, Molina TJ, Haioun C, Bosly A.

Fonte‎: Lancet Oncol 2013;14(6):525-33.

Indicizzato‎: PubMed 23578722

DOI‎: 10.1016/S1470-2045(13)70122-0

https://www.ncbi.nlm.nih.gov/pubmed/23578722 (apre una nuova finestra)

Azacitidine and venetoclax in previously untreated acute myeloid leukemia. (apre una nuova finestra)

DiNardo CD, Jonas BA, Pullarkat V, Thirman MJ, Garcia JS, Wei AH, Konopleva M, Döhner H, Letai A, Fenaux P, Koller E, Havelange V, Leber B, Esteve J, Wang J, Pejsa V, Hájek R, Porkka K, Illés Á, Lavie D, Lemoli RM, Yamamoto K, Yoon SS, Jang JH, Yeh SP, Turgut M, Hong WJ, Zhou Y, Potluri J, Pratz KW

Fonte‎: N Engl J Med 2020;383(7):617-29.

Indicizzato‎: PubMed 32786187

DOI‎: 10.1056/NEJMoa2012971

https://www.ncbi.nlm.nih.gov/pubmed/32786187 (apre una nuova finestra)

Treatment of acute leukaemia in adult Jehovah's Witnesses. (apre una nuova finestra)

El Chaer F, Ballen KK

Fonte‎: Br J Haematol 2020;190(5):696-707.

Indicizzato‎: PubMed 31693175

DOI‎: 10.1111/bjh.16284

https://www.ncbi.nlm.nih.gov/pubmed/31693175 (apre una nuova finestra)

Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. (apre una nuova finestra)

Friedman HS, Prados MD, Wen PY, Mikkelsen T, Schiff D, Abrey LE, Yung WK, Paleologos N, Nicholas MK, Jensen R, Vredenburgh J, Huang J, Zheng M, Cloughesy T.

Fonte‎: J Clin Oncol 2009;27(28):4733-40.

Indicizzato‎: PubMed 19720927

DOI‎: 10.1200/JCO.2008.19.8721

https://www.ncbi.nlm.nih.gov/pubmed/19720927 (apre una nuova finestra)

Successful treatment of a Jehovah's Witness with acute promyelocytic leukemia. (apre una nuova finestra)

Fujita H, Maruta A, Koharazawa H, Hattori M, Tomit N, Kodama F, Mohri H, Okubo T.

Fonte‎: Int J Hematol 1997;65(4):415-6.

Indicizzato‎: PubMed 9195782

https://www.ncbi.nlm.nih.gov/pubmed/9195782 (apre una nuova finestra)

Immediate or delayed therapy with 2-CdA for hairy cell leukemia in Jehova's Witness? (apre una nuova finestra)

Juliusson G.

Fonte‎: Am J Hematol 1996;53(1):49.

Indicizzato‎: PubMed 8813099

DOI‎: 10.1002/(SICI)1096-8652(199609)53:1<49::AID-AJH12>3.0.CO;2-Z

https://www.ncbi.nlm.nih.gov/pubmed/8813099 (apre una nuova finestra)

Tailored therapy of adult acute leukaemia in Jehovah's Witnesses: unjustified reluctance to treat. (apre una nuova finestra)

Laszlo D, Agazzi A, Goldhirsch A, Cinieri S, Bertolini F, Rabascio C, Pruneri G, Calabrese L, Cocquio A, Martinelli G.

Fonte‎: Eur J Haematol 2004;72(4):264-7.

Indicizzato‎: PubMed 15089764

DOI‎: 10.1111/j.0902-4441.2003.00211.x

https://www.ncbi.nlm.nih.gov/pubmed/15089764 (apre una nuova finestra)

Successful treatment of acute promyelocytic leukemia in a pregnant Jehovah's Witness with all-trans retinoic acid, rhG-CSF, and erythropoietin. (apre una nuova finestra)

Lin CP, Huang MJ, Liu HJ, Chang IY, Tsai CH.

Fonte‎: Am J Hematol 1996;51(3):251-2.

Indicizzato‎: PubMed 8619417

DOI‎: 10.1002/(SICI)1096-8652(199603)51:3<251::AID-AJH20>3.0.CO;2-I

https://www.ncbi.nlm.nih.gov/pubmed/8619417 (apre una nuova finestra)

Cytarabine dose for acute myeloid leukemia. (apre una nuova finestra)

Löwenberg B, Pabst T, Vellenga E, van Putten W, Schouten HC, Graux C, Ferrant A, Sonneveld P, Biemond BJ, Gratwohl A, de Greef GE, Verdonck LF, Schaafsma MR, Gregor M, Theobald M, Schanz U, Maertens J, Ossenkoppele GJ; Dutch-Belgian Cooperative Trial Group for Hemato-Oncology (HOVON) and Swiss Group for Clinical Cancer Research (SAKK) Collaborative Group.

Fonte‎: N Engl J Med 2011;364(11):1027-36.

Indicizzato‎: PubMed 21410371

DOI‎: 10.1056/NEJMoa1010222

https://www.ncbi.nlm.nih.gov/pubmed/21410371 (apre una nuova finestra)

Myeloablative therapy and bone marrow transplantation in Jehovah's Witnesses with malignancies: single center experience. (apre una nuova finestra)

Mazza P, Prudenzano A, Amurri B, Palazzo G, Pisapia G, Stani L, Pricolo G.

Fonte‎: Bone Marrow Transplant 2003;32(4):433-6.

Indicizzato‎: PubMed 12900781

DOI‎: 10.1038/sj.bmt.1704179

https://www.ncbi.nlm.nih.gov/pubmed/12900781 (apre una nuova finestra)

Ivosidenib and azacitidine in IDH1-mutated acute myeloid leukemia. (apre una nuova finestra)

Montesinos P, Recher C, Vives S, Zarzycka E, Wang J, Bertani G, Heuser M, Calado RT, Schuh AC, Yeh SP, Daigle SR, Hui J, Pandya SS, Gianolio DA, de Botton S, Döhner H

Fonte‎: N Engl J Med. 2022;386(16):1519-31. 

Indicizzato‎: PubMed 35443108

DOI‎: 10.1056/NEJMoa2117344

https://pubmed.ncbi.nlm.nih.gov/35443108/ (apre una nuova finestra)

Effect of chemotherapy delays and dose reductions on progression free and overall survival in the treatment of epithelial ovarian cancer. (apre una nuova finestra)

Nagel CI, Backes FJ, Hade EM, Cohn DE, Eisenhauer EL, O'Malley DM, Fowler JM, Copeland LJ, Salani R.

Fonte‎: Gynecol Oncol 2012;124(2):221-4.

Indicizzato‎: PubMed 22055764

DOI‎: 10.1016/j.ygyno.2011.10.003

https://www.ncbi.nlm.nih.gov/pubmed/22055764 (apre una nuova finestra)

The treatment of acute lymphoblastic leukemia in Jehovah's Witnesses and patients who cannot accept blood products. (apre una nuova finestra)

Nguyen N, Madarang E, Alencar A, Watts J, Bradley T

Fonte‎: Leuk Res Rep. 2022 25;18:100355.

Indicizzato‎: PubMed 36338830

DOI‎: 10.1016/j.lrr.2022.100355

https://pubmed.ncbi.nlm.nih.gov/36338830/ (apre una nuova finestra)

High-dose chemotherapy without transfusion for Philadelphia chromosome negative B-cell acute lymphoblastic leukemia in two Jehovah's Witnesses patients: a feasible option in the age of hematopoietic growth factors. (apre una nuova finestra)

Perol L, Grignano E, Contejean A, Gastaud L, Legoff M, Franchi P, Deau-Fischer B, Willems L, Bouscary D, Tamburini J

Fonte‎: Leuk Lymphoma. 2019;60(9):2324-7.

Indicizzato‎: PubMed 30773115

DOI‎: 10.1080/10428194.2019.1577414

https://www.ncbi.nlm.nih.gov/pubmed/30773115 (apre una nuova finestra)

Hematopoietic growth factors: personalization of risks and benefits. (apre una nuova finestra)

Puhalla S, Bhattacharya S, Davidson NE.

Fonte‎: Mol Oncol 2012;6(2):237-41.

Indicizzato‎: PubMed 22497867

DOI‎: 10.1016/j.molonc.2012.03.001

https://www.ncbi.nlm.nih.gov/pubmed/22497867 (apre una nuova finestra)

Bloodless chimeric antigen receptor (CAR) T-cell therapy in Jehovah's Witnesses. (apre una nuova finestra)

Riedell PA, Wu M, Collins JM, Gideon JM, Jakubowiak AJ, Kline JP, Kosuri S, Liu H, Smith SM, Bishop MR

Fonte‎: Leuk Lymphoma 2021;62(6):1497-501.

Indicizzato‎: PubMed 33535838

DOI‎: 10.1080/10428194.2021.1876868

https://www.ncbi.nlm.nih.gov/pubmed/33535838 (apre una nuova finestra)

Ivosidenib induces deep durable remissions in patients with newly diagnosed IDH1-mutant acute myeloid leukemia. (apre una nuova finestra)

Roboz GJ, DiNardo CD, Stein EM, de Botton S, Mims AS, Prince GT, Altman JK, Arellano ML, Donnellan W, Erba HP, Mannis GN, Pollyea DA, Stein AS, Uy GL, Watts JM, Fathi AT, Kantarjian HM, Tallman MS, Choe S, Dai D, Fan B, Wang H, Zhang V, Yen KE, Kapsalis SM, Hickman D, Liu H, Agresta SV, Wu B, Attar EC, Stone RM

Fonte‎: Blood 2020;135(7):463-71.

Indicizzato‎: PubMed 31841594

DOI‎: 10.1182/blood.2019002140

https://www.ncbi.nlm.nih.gov/pubmed/31841594 (apre una nuova finestra)

Bloodless (transfusion-free) hematopoietic stem cell transplants: the Mexican experience. (apre una nuova finestra)

Ruiz-Argüelles GJ, Morales-Toquero A, López-Martínez B, Tarín-Arzaga LD, Manzano C.

Fonte‎: Bone Marrow Transplant 2005;36(8):715-20.

Indicizzato‎: PubMed 16113672

DOI‎: 10.1038/sj.bmt.1705126

https://www.ncbi.nlm.nih.gov/pubmed/16113672 (apre una nuova finestra)

A Mexican way to cope with stem cell grafting. (apre una nuova finestra)

Ruiz-Delgado GJ, Ruiz-Argüelles GJ.

Fonte‎: Hematology 2012;17 Suppl 1:S195-7.

Indicizzato‎: PubMed 22507819

DOI‎: 10.1179/102453312X13336169157130

https://www.ncbi.nlm.nih.gov/pubmed/22507819 (apre una nuova finestra)

Management of acute promyelocytic leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet. (apre una nuova finestra)

Sanz MA, Grimwade D, Tallman MS, Lowenberg B, Fenaux P, Estey EH, Naoe T, Lengfelder E, Büchner T, Döhner H, Burnett AK, Lo-Coco F.

Fonte‎: Blood 2009;113(9):1875-91.

Indicizzato‎: PubMed 18812465

DOI‎: 10.1182/blood-2008-04-150250

https://www.ncbi.nlm.nih.gov/pubmed/18812465 (apre una nuova finestra)

SCT in Jehovah's Witnesses: the bloodless transplant. (apre una nuova finestra)

Sloan JM, Ballen K.

Fonte‎: Bone Marrow Transplant 2008;41(10):837-44.

Indicizzato‎: PubMed 18246110

DOI‎: 10.1038/bmt.2008.5

https://www.ncbi.nlm.nih.gov/pubmed/18246110 (apre una nuova finestra)

Treatment of acute myelogenous leukemia with outpatient azacitidine. (apre una nuova finestra)

Sudan N, Rossetti JM, Shadduck RK, Latsko J, Lech JA, Kaplan RB, Kennedy M, Gryn JF, Faroun Y, Lister J.

Fonte‎: Cancer 2006;107(8):1839-43.

Indicizzato‎: PubMed 16967444

DOI‎: 10.1002/cncr.22204

https://www.ncbi.nlm.nih.gov/pubmed/16967444 (apre una nuova finestra)

Isolated limb perfusion for an irresectable melanoma recurrence in a Jehovah's Witness. (apre una nuova finestra)

van Akkooi AC, Golab-Schwarz HD, Eggermont AM, van Geel AN.

Fonte‎: Eur J Cardiothorac Surg 2006;30(2):408-10.

Indicizzato‎: PubMed 16829108

DOI‎: 10.1016/j.ejcts.2006.04.020

https://www.ncbi.nlm.nih.gov/pubmed/16829108 (apre una nuova finestra)

Management of cytopenias in patients with myelofibrosis treated with ruxolitinib and effect of dose modifications on efficacy outcomes. (apre una nuova finestra)

Verstovsek S, Gotlib J, Gupta V, Atallah E, Mascarenhas J, Quintas-Cardama A, Sun W, Sarlis NJ, Sandor V, Levy RS, Kantarjian HM, Mesa RA.

Fonte‎: Onco Targets Ther 2013;7:13-21.

Indicizzato‎: PubMed 24368888

DOI‎: 10.2147/OTT.S53348

https://www.ncbi.nlm.nih.gov/pubmed/24368888 (apre una nuova finestra)

Bevacizumab plus irinotecan in recurrent glioblastoma multiforme. (apre una nuova finestra)

Vredenburgh JJ, Desjardins A, Herndon JE 2nd, Marcello J, Reardon DA, Quinn JA, Rich JN, Sathornsumetee S, Gururangan S, Sampson J, Wagner M, Bailey L, Bigner DD, Friedman AH, Friedman HS.

Fonte‎: J Clin Oncol 2007;25(30):4722-9.

Indicizzato‎: PubMed 17947719

DOI‎: 10.1200/JCO.2007.12.2440

https://www.ncbi.nlm.nih.gov/pubmed/17947719 (apre una nuova finestra)

Venetoclax plus LDAC for newly diagnosed AML ineligible for intensive chemotherapy: a phase 3 randomized placebo-controlled trial. (apre una nuova finestra)

Wei AH, Montesinos P, Ivanov V, DiNardo CD, Novak J, Laribi K, Kim I, Stevens DA, Fiedler W, Pagoni M, Samoilova O, Hu Y, Anagnostopoulos A, Bergeron J, Hou JZ, Murthy V, Yamauchi T, McDonald A, Chyla B, Gopalakrishnan S, Jiang Q, Mendes W, Hayslip J, Panayiotidis P

Fonte‎: Blood 2020;135(24):2137-45.

Indicizzato‎: PubMed 32219442

DOI‎: 10.1182/blood.2020004856

https://www.ncbi.nlm.nih.gov/pubmed/32219442 (apre una nuova finestra)

Acute lymphoblastic leukaemia in a Jehovah's Witness: a management dilemma. (apre una nuova finestra)

Zhou L, Mohsen A, Khan MA, Guthrie T.

Fonte‎: J Chemother 2014;26(3):184-6.

Indicizzato‎: PubMed 24621157

DOI‎: 10.1179/1973947813Y.0000000130

https://www.ncbi.nlm.nih.gov/pubmed/24621157 (apre una nuova finestra)